The escalating number of genetic disorders in newborns has raised the demand of prenatal tests among the populace. Prenatal testing has gained traction over the last few years, since, the tests detect numerous genetic disorders present in the fetus and help in early prevention of the diseases. It consists of many methods such as amniocentesis, chronic villus sampling, maternal serum screening, and non-invasive prenatal testing (NIPT). NIPT has been successfully used to screen pregnant women at high risk of developing fetal chromosomal aneuploidies such as Down syndrome (trisomy 21), Edwards syndrome (trisomy 18), Patau syndrome (trisomy 13), and Turner syndrome (monosomy X), along with fetal sex determination. Hence, the populace is more inclined towards NIPT as compared to other prenatal tests, and this is propelling the growth of the global NIPT market, along with other factors such as technological innovation and advancement, increasing genetic disorder/abnormalities, and government support & regulations.
The NIPT market is predominantly driven by product launches from key players, followed by partnerships and collaborations. Also, established players in the market are engaging in acquisitions of small market players for gaining an upper hand in the market. Illumina Inc., one of the key players of the market, extended its partnership with Hamilton Robotics and strengthening it “through the collaborative development of the VeriSeq™ NIPT Solution for high-throughput non-invasive prenatal testing (NIPT)1.” This automated, next generation sequencing test is more accurate, with faster result and lower cost than any other evasive techniques.
Another NIPT giant, LifeCodexx AG, announced in December 2016, that “CE marking of its PrenaTest® BioIT analysis software based on an innovative methylation-specific qPCR assay for the detection of fetal trisomy 21 (qNIPT). Now the proprietary PrenaTest® software is cleared for the analysis of data from next generation sequencing as well as from qPCR2.” According to Michael Lutz, Chief Executive Officer of LifeCodexx AG, “Our smart qNIPT will allow more pregnant women to opt for NIPT as a reliable and affordable prenatal testing method which provides rapid results under highest quality standards2.”
With a highly dynamic environment, NIPT market is moving towards a robust growth in the coming years. Acknowledging the increasing potential of the market, BIS Research has compiled a report titled ‘Global Non-Invasive Prenatal Testing (NIPT) Market -Analysis and Forecast (2017-2023)’, which is a comprehensive analysis of the global NIPT market including a segmentation of the market into test value and volume, and geographical region with detailed country analysis which enables the user gain a multi-dimensional view of the market.
According to the analyst at BIS Research, “The market is witnessing a wide range of alliances of NIPT developers with local diagnostic service providers. Moreover, awareness about early detection of prenatal abnormalities is gradually increasing in these regions. Therefore, the NIPT market in RoW and Asia Pacific is likely to witness the highest CAGR of 22.2% and 18.8%, respectively, in terms of volume.”
The study also includes an all-inclusive insight into various forms of developments, market trends and strategies. While underlining the key driving and restraining factors for the NIPT market, the report also provides a comprehensive understanding in terms of competitive landscape, market share analysis, competitor benchmarking (matrices), and their positioning within the global NIPT market. Some of the key players profiled in the report are Roche, Natera, Illumina, LabCorp, LifeCodexx, BGI Diagnostics, Premaitha and Berry Genomics, among others.
2 B3C Newswire